Clinical trials located in

Belfast

Belfast city is located in United Kingdom. Currently, 15 clinical trials are being conducted in this city.

Belfast, the capital city of Northern Ireland, United Kingdom, boasts a rich tapestry of history and culture. Founded in the 17th century, it became a major industrial powerhouse, notably in shipbuilding, with the famous RMS Titanic constructed in its Harland and Wolff shipyard. The city has a vibrant arts scene, exemplified by the annual Belfast International Arts Festival. Belfast is also known for its Victorian architecture, including the grand City Hall and the Queen’s University. The peace walls, murals, and the Titanic Belfast museum are poignant reminders of its complex past and resilience.

  • CT-EU-00041556

    New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    BelgiumFranceItalyPolandSpainUnited Kingdom
  • Studying camlipixant for chronic cough treatment

    This study involves a year-long study of a drug known as Camlipixant (BLU-5937). The aim is to evaluate its potential effectiveness in treating persistent cough in adults who have not found relief with alternative treatments. The methodology involves giving Camlipixant (BLU-5937) to some participants and a placebo to others. The allocation of the real drug or placebo is not disclosed to all study participants. After 12 weeks of taking Camlipixant, your daily cough frequency will be assessed. The purpose of this evaluation is to determine whether it has a noticeable effect. Additionally, participants will be asked to self-assess the severity of their cough on a scale. Finally, participants will be asked to complete a survey detailing the impact of cough on everyday life, emotional well-being and interpersonal relationships.

    BelgiumFranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing birtamimab for safety and effectiveness in patients with severe AL Amyloidosis

    This medical study aims to investigate a drug called birtamimab to understand if it effectiveness and is safe for people in the advanced stage (Mayo Stage IV) of a disease called AL Amyloidosis. In this study, scientists are comparing the outcomes of two groups of people: one group receiving birtamimab in addition to standard-of-care chemotherapy, and another group receiving a neutral drug (placebo) along with standard-of-care chemotherapy. The goal is to assess whether the group receiving birtamimab has better results or outcomes compared to the group receiving the placebo. Around 150 patients with AL Amyloidosis will join the study. Patients will be chosen randomly to either receive birtamimab or placebo.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    AustriaBelgiumBulgariaDenmarkFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Testing Samuraciclib & Elacestrant for Advanced Breast Cancer

    This study tests two drugs, Samuraciclib and Elacestrant, in people with a particular type of advanced breast cancer. This cancer is influenced by hormones (HR+) and does not contain a molecule known as HER2. At the beginning of the study, doctors will give a small group of patients increasing doses of these drugs to see what a safe dose is. This is the “dose escalation phase”. This safe dose will then be used in a larger group to see how well the drug combination fights cancer. During this time, you will be closely monitored for the effects of your medicines, including any side effects. Clinical trials also aim to examine how long it takes for the cancer to worsen or progress during the treatment phase, as well as to see how many people overall will benefit from the treatment.

    FranceSpainUnited Kingdom
  • Study on durvalumab with oleclumab or monalizumab for lung cancer

    This is a study about two new treatments for a type of lung cancer called Non-small Cell Lung Cancer. This study is for adults with Stage III unresectable non-small cell lung cancer who’ve already had chemoradiation. It’s testing the effects of durvalumab combined with either oleclumab or monalizumab. The treatments are given through IV on a 28-day cycle for up to 12 months. The main goal is to see if these drug combinations can stop cancer from progressing and help patients live longer.

    FranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in United Kingdom:

.